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Abstract 
Background: The dependency of miRNA abundance from physiological processes such as exercises remains partially 
understood. We set out to analyze the effect of physical exercises on miRNA profiles in blood and plasma of endur-
ance and strength athletes in a systematic manner and correlated differentially abundant miRNAs in athletes to 
disease miRNAs biomarkers towards a better understanding of how physical exercise may confound disease diagnosis 
by miRNAs.
Methods: We profiled blood and plasma of 29 athletes before and after exercise. With four samples analyzed for each 
individual we analyzed 116 full miRNomes. The study set-up enabled paired analyses of individuals. Affected miRNAs 
were investigated for known disease associations using network analysis.
Results: MiRNA patterns in blood and plasma of endurance and strength athletes vary significantly with differences 
in blood outreaching variations in plasma. We found only moderate differences between the miRNA levels before 
training and the RNA levels after training as compared to the more obvious variations found between strength ath-
letes and endurance athletes. We observed significant variations in the abundance of miR-140-3p that is a known cir-
culating disease markers (raw and adjusted p value of 5 × 10−12 and 4 × 10−7). Similarly, the levels of miR-140-5p and 
miR-650, both of which have been reported as makers for a wide range of human pathologies significantly depend 
on the training mode. Among the most affected disease categories we found acute myocardial infarction. MiRNAs, 
which are up-regulated in endurance athletes inhibit VEGFA as shown by systems biology analysis of experimentally 
validated target genes.
Conclusion: We provide evidence that the mode and the extent of training are important confounding factors for a 
miRNA based disease diagnosis.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
It is increasingly recognized that biomarkers are not 
only affected by pathological processes, but likewise by 
other environmental factors. Among the most popu-
lar examples are cardiovascular biomarkers such as 
cTnT, hs-cTnT, BNP or NT-proBNP. These biomark-
ers are prone to alterations due to strenuous exercise, as 
recently reviewed by Sedaghat-Hamedani [1]. Similarly, 
more complex marker signatures may also depend sig-
nificantly on the training status. One class of such novel 
marker candidates are small non-coding RNAs, so-called 
miRNAs.
Their importance for a wide range of conditions is 
currently explored and validated. Beyond tissue based 
miRNA profiles, circulating patterns have gained increas-
ing importance. The role of circulating miRNAs in differ-
ent disease classes has been reviewed in depth. Examples 
include the two most common causes for death in devel-
oped countries, cancer [2] and cardiovascular disorders 
[3]. In addition to their promising role as diagnostic and 
prognostic markers for human pathologies, miRNAs 
Open Access
Journal of 
Translational Medicine
*Correspondence:  andreas.keller@ccb.uni-saarland.de 
†Anne Hecksteden and Petra Leidinger contributed equally to this work 
3 Chair for Clinical Bioinformatics, Medical Department, Saarland 
University, Building E2.1, 66125 Saarbrücken, Germany
Full list of author information is available at the end of the article
Page 2 of 13Hecksteden et al. J Transl Med  (2016) 14:219 
have also been correlated to different exercise modes and 
the overall physical performance capacity. Especially in 
the light of more complex marker patterns that are not 
only correlated to diseases but also to physiological pro-
cesses such as exercises it is essential to understand how 
respective physiological processes can confound disease 
diagnosis and prognosis.
Previously, we reported that exercise of elite endur-
ance athletes had a limited direct influence on miRNAs 
in blood [4]. In the same study we reported that respec-
tive changes in the blood have lower effect sizes as com-
pared to the impact of pathophysiological changes. In 
other studies, the impact of exercise on different miRNAs 
has been explored. Melo and co-workers have discovered 
a key role of miR-214 in rats [5]. While this miRNA was 
down-regulated in the cohort undergoing exercise, the 
target gene SERCA2a increased. Similarly, Liu and co-
workers demonstrated that miR-222 is of key importance 
for cardiac growth, which is induced by exercise. Fur-
thermore miR-222 protects against pathological cardiac 
remodeling [6]. While these studies have been carried 
out in animals, case–control studies have been also con-
ducted in human athletes. Wardle et al. have carried out 
a study on plasma of endurance and strength athletes [7]. 
They investigated three cohorts (strength athletes, power 
athletes and untrained individuals, n  =  10) and found 
differential regulation of circulating miRNAs such as 
miR-222. A more elaborate overview describing the role 
of circulating microRNAs in response to exercise can be 
found in two recently published comprehensive reviews 
by Xu [8] and Altana [9].
Especially with increasing evidence of miRNA pro-
files for diagnostic or prognostic purposes in human 
pathologies putative confounding variables are also gain-
ing increasing attention. Beyond straightforward con-
founders of miRNA profiles such as the age and gender 
[10] regular exercise on a long term as well as short term 
increase after fatigue (e.g. in competitions or training 
camps) may also impact the miRNA profile. Concord-
antly, Gomes and co-workers described the implications 
on clinical diagnostics of using microRNA-based bio-
markers in exercise [11].
Despite multiple studies on circulating miRNAs related 
to fatigue status, it is hard to compare different train-
ing forms, athlete types and the variations in blood and 
plasma. In the available studies, different protocols for 
extracting the miRNAs, profiling them and evaluat-
ing them have been applied. This renders a meta-ana-
lytical analysis error prone. We thus set to implement a 
standardized repository of miRNAs related to physical 
exercise.
In our previous proof-of-concept study [4] we did not 
distinguished between strength and endurance athletes, 
but analyzed less trained individuals as controls. In addi-
tion, we analyzed whole blood only. In the present study, 
we selected a study set-up that allows for paired and 
unpaired comparison of the most important factors. In 
detail, we measured the full miRNomes (1) of strength 
athletes and endurance athletes (2) before and after a 
6-days simulated training camp in (3) plasma and blood. 
With all combinations included we profiled a total of 8 
different groups. Since the comparisons “prior and post 
training” and “plasma and blood” were done analyzing 
same individuals, it was possible to do a paired testing 
for the respective comparisons. An unpaired analysis was 
required only for the comparison between strength and 
endurance athletes. Altogether, we profiled 29 athletes 
corresponding to 29 biological replicates. For each ath-
lete we measured the miRNomes of the following four 
profiles: “prior training plasma”, “post training plasma”, 
“prior training blood” and “post training blood”, totaling 
116 miRNomes.
Methods
Design
Twenty nine well-trained male athletes [15 endurance 
athletes (cyclists) and 14 strength athletes] volunteered 
for this prospective, short-term training trial. Tests were 
conducted at baseline following a 2-day run in resting 
phase as well as after induction of fatigue by a discipline 
specific, strenuous training program. The 6-day training 
period consisted of two training sessions a day, with the 
exception of day 4 when no morning session was sched-
uled. Care was taken to implement a demanding, train-
ing design for either discipline resulting in high levels of 
physical strain and fatigue. To verify effective, reversible 
induction of fatigue established fatigue markers [12] were 
assessed.
The study was undertaken in accordance with the Dec-
laration of Helsinki and approved by the local ethics 
committee (Ärztekammer des Saarlandes, Saarbrücken, 
Germany, ID 46/13). All athletes provided written 
informed consent prior to participation. All tests were 
conducted in a University department (Cyclists: Saarland 
University, Germany; Strength athletes: Ruhr Universität 
Bochum, Germany).
Blood sampling and miRNA measurement
After reporting to the laboratory at a standardized time 
(between 8 and 10 a.m., intra-individually same hour for 
all tests) subjects rested in the supine position for 10 min 
prior to blood collection. A winged cannula was inserted 
into the antecubital vein during a short stasis (max. 
30 s.). Serum and plasma aliquots were frozen at −80 °C 
within 60 min from blood collection and stored for later 
analysis. Whole-blood samples for the determination 
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of miRNA expression were collected and stored in spe-
cial tubes (PAXgene blood RNA tube, Becton–Dickin-
son, Germany). For miRNA measurement, blood and 
plasma samples have been used while further labora-
tory parameters (details below) were determined from 
serum samples. miRNA extraction of blood and plasma 
samples have been carried out as described previously 
and according to manufacturer’s instructions [4]. For 
the strength athletes, plasma has been diluted in a ratio 
of 1:2. The quality of the samples has been controlled by 
Bioanalyzer measurements and the RNA 6000 Nano kit. 
Microarray profiling has been carried out using Agilent 
SurePrint V16 Human miRNA Microarrays (miRBase 
v16) microarrays encompassing 1205 different miRNAs, 
as described previously [4] and following the manufac-
turer’s instructions. Each miRNA was measured for each 
patient by 40 on-chip technical replicates. The microar-
ray data are available in Additional file 1: Table S1.
Further laboratory parameters
As further blood parameters we included the hemoglobin 
concentration (Hb), Erythrocyte, Leucocyte and Throm-
bocyte count, creatine kinase (CK), urea, free-testoster-
one, c reactive protein (CRP), cortisol, glutamine (Gln) 
and glutamate (Glu) concentration, insulin like growth 
factor 1 (IGF-1), IGF-1 binding protein 3 (IGF-BP3), 
tumor necrosis factor (TNF), interleukin 6 (IL-6), and 
human growth hormone (HGH) at different time points.
Statistical analysis
Following feature extraction using the Agilent’s image 
processing software with standard parameters, expres-
sion values were subjected to quantile normalization. 
All downstream statistical calculations have been car-
ried out in R version 3.0.2. Principal Component Analysis 
has been done using the prcomp function, for ANOVA, 
the aov function was used. Hierarchical clustering was 
done using the Euclidian distance measure and complete 
linkage clustering by the hclust package. Visualization 
of heatmaps has been done by a modified version of the 
heatmap.2 function.
Correlations of the identified miRNA to diseases were 
calculated using the downloaded version of the Human 
microRNA Disease Database (HMDD) (Version 2.0, data 
accessed on May, 28th, 2016) [13]. Before relating the 
miRNAs to the HMDD, mature forms were mapped to 
the precursors to ensure compatibility with the HMDD. 
We used only the “circulating” subset of the HMDD. 
Prediction of pathways has been carried out using the 
gene (miRNA) set enrichment tool miEAA [14] (http://
www.ccb.uni-saarland.de/mieaa_tool/). KEGG pathway 
and gene ontology analysis has been performed using 
miRTargetLink [15] (http://www.ccb.uni-saarland.de/
mirtargetlink) and the API to GeneTrail [16] and Gen-
eTrail2 [17].
Availability of data and supporting materials
All miRNA measurements with meta-data have been 
made freely available (Additional file 1: Table S1).
Results
To understand the influence of physical exercises on the 
miRNA abundance and to relate the affected miRNAs 
to known disease associated miRNAs we profiled 116 
miRNOmes from 58 plasma and 58 paired blood sam-
ples of well-trained individuals (endurance and strength 
athletes) before and after a 6-day training period. The 
study-set up is sketched in Fig. 1. To limit the influence 
of markers close to the background and contributing 
more noise than signal to the analysis we removed low 
abundant miRNAs and performed the analysis with 388 
miRNAs that were expressed in the majority of individu-
als. Effective induction of fatigue could be confirmed 
by changes in standard blood-born markers. Creatine 
kinase increased significantly in endurance and strength 
athletes [endurance: +56 ± 74 U/l (p = 0.006); strength 
+664 ± 817 U/l (p = 0.013)]. Urea increased significantly 
in endurance athletes (+11 ±  10  mg/dl p  <  0.001). For 
strength athletes the difference in urea concentration 
failed to reach statistical significance [+4  ±  11  mg/dl 
(p = 0.184)].
Difference in composition of miRNA profiles
To understand how divergent miRNA profiles in blood 
and plasma of strength and endurance athletes are and 
how the current training and individual variations con-
tribute to the profiles we quantified the effect of these 
four variables on the miRNA abundance. Principal vari-
ance component analysis highlighted that the specimen 
type (blood versus plasma) had the largest impact on the 
profiles followed by the athlete type (endurance versus 
strength athletes). Individual variations and the training 
effect contributed substantially less to the overall profiles. 
While the large deviation between blood and plasma 
miRNomes is known the differences between strength 
and endurance athletes was surprisingly high. For visu-
alizing the effect of the two most important parameters 
we performed principal component analysis and colored 
the individual samples with respect to the specimens 
and the athlete type (see Fig. 2a). The first PC perfectly 
distinguishes between plasma and blood profiles while 
the second PC well separates endurance from strength 
athletes. The figure also indicates that the variability in 
plasma profiles exceeded the variability of blood pro-
files. Nevertheless, blood profiles differentiated more 
precisely between strength and endurance athletes. To 
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demonstrate this we performed PCA separately for blood 
(Fig. 2b) and plasma (Fig. 2c), providing evidence that for 
the blood-borne miRNA profiles strength athletes can 
be perfectly separated from endurance athletes while in 
case of plasma profiles a limited overlap is observed. A 
similar conclusion can be drawn from an unsupervised 
hierarchical clustering, presented in Fig. 3. The heat map 
outlines a clear cut between blood and plasma profiles. 
For the blood profiles on the right hand side of this plot, 
almost all strength and endurance athletes cluster well 
together.
These results suggest that the type of training has a 
substantial impact on plasma and blood profiles of indi-
viduals. The miRNA profiles, especially from blood, can 
thus likely be used as molecular monitor for the strength 
and stamina of athletes.
Specific miRNAs as indicators for different training modes
The described substantial variation between endurance 
and strength athletes in general let us ask on specific 
miRNAs that are differentially regulated in blood and 
plasma for the two athlete types. Following adjustment 
for multiple testing we observed in plasma samples 231 
differentially regulated miRNAs. Of those, almost equal 
parts were higher (108 miRNAs)/lower (123) expressed in 
endurance athletes as compared to strength athletes. The 
most significantly down-regulated miRNA was hsa-miR-
513b-5p, the most significantly up-regulated miRNAs 
was hsa-miR-140-5p, both with a p value of 3 × 10−13. In 
blood off the same athletes, 265 differentially regulated 
miRNAs following adjustment for multiple testing were 
detected. Of these 139 were higher expressed in endur-
ance athletes while 126 were lower expressed. Most sig-
nificantly down-regulated was hsa-miR-650 (p value of 
4 × 10−23), most significantly up-regulated was hsa-miR-
3620-3p (p value of 6 ×  10−19). The expression of miR-
650 is exemplarily presented in Fig. 4a. As detailed there, 
we calculated a slight correlation between the differential 
regulation of miRNAs between strength and endurance 
athletes in blood as well as plasma (Pearson Correlation 
of 0.16). Among the miRNAs that showed largest con-
cordance was miR-140-5p, the most significantly up-
regulated miRNA in plasma was likewise significantly 
up-regulated in blood of endurance athletes (Fig. 4b).
Taken together, our results suggest that miRNAs, pre-
liminary measured from blood, are well suited to indicate 
the overall status of an athlete and whether the respective 
athlete is trained mostly towards endurance or strength.
Fig. 1 Study set-up. Horizontal arrays represent paired analyses, vertical arrows unpaired statistical calculations
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miRNA enrichment of markers depending on training 
mode
In the light of the substantial changes in the miRNA rep-
ertoire of endurance and strength athletes we applied 
a statistical set enrichment analysis to understand on 
which pathways and biological categories the dys-regu-
lated miRNAs participate using miEAA (http://www.ccb.
uni-saarland.de/mieaa_tool/). In the miEAA data reposi-
tory we also integrated data of more than 25 human 
pathologies to allows for detecting significant enrichment 
of disease markers in our miRNA sets. The calculations 
have been carried out for plasma and blood separately. 
With respect to disease associations, we calculated sig-
nificant enrichment for miRNAs that are up- or down 
regulated in acute myocardial infarction (FDR adjusted 
significance value of 0.04 and 0.01, respectively), as the 
running sum statistics in Fig. 5 demonstrate. These plots 
show on the x-axis the rank of differential regulation (left 
miRNAs are up-regulated in strength athletes, right miR-
NAs in endurance athletes). The y-axis shows the running 
sum value, i.e. the higher or respectively lower the curve 
gets the more accumulation of miRNAs in the considered 
a
b
c
Fig. 2 Principal component analysis. a presents PCA of all data points (red blood samples, blue plasma samples). b contains only blood and c only 
plasma samples (orange strength athletes, blue endurance athletes)
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categories are observed. We also found that the miR-
NAs that are higher expressed in endurance athletes as 
compared to strength athletes are enriched in differ-
ent immune cells (CD15: 2 × 10−5; CD56: 0.0001; CD3: 
0.0002, CD14: 0.0003, CD19: 0.0008). For blood samples 
substantially less significant results were observed. Most 
notably, we calculated enrichment of miRNAs target-
ing ischemia genes in endurance athletes. This opens the 
question on the impact of miRNAs differentially regu-
lated in endurance and strength athletes.
Pathway analysis of miRNA targets
Dys-regulation of miRNAs should lead to a dys-regula-
tion of target genes that in turn might have an influence 
on the phenotype. Following this hypothesis we extracted 
target genes of miRNAs that are differentially regulated 
in plasma of strength and endurance athletes. To select 
the most relevant regulators we selected miRNAs with 
adjusted significance value below 10−4 and included only 
experimentally validated targets. For the 63 dys-regu-
lated miRNAs we extracted 189 targets. Some of these 
have been targeted by different miRNAs, leaving 162 
unique genes. The respective miRNAs and target genes 
are sketched as interaction network in Fig. 6. A network 
analysis aiming to discover the most central gene (i.e. a 
gene which is targeted by many miRNAs) highlighted 
VEGFA. The respective part of the network is also pre-
sented in Fig. 6. VEGFA is targeted by five miRNAs, the 
previously mentioned miR-140-5p and also miR-378a-3p, 
miR-361-5p, miR-93-5p and miR-17-5p. All these 
Fig. 3 Hierarchical clustering of all samples. The heatmap indicates that substantial differences between blood and plasma are observed but also 
profiles between endurance and strength athletes generally cluster together
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miRNAs are significantly up-regulated in endurance ath-
letes compared to strength athletes (1.8 fold to 3.1 fold).
To further annotate the genes in the network we car-
ried out functional gene enrichment analysis. We com-
pared the accumulation of the 162 unique miRNA targets 
on KEGG pathways and Gene Ontology categories to the 
background distribution of all genes that are targeted by 
at least one miRNA with strong evidence (2098 genes). 
Following adjustment for multiple testing according to 
Benjamini-Hochberg and excluding categories with a 
less than three-fold enrichment of genes, we found 8 
significant categories from the gene ontology (biologi-
cal process) and ten KEGG pathways. Remarkably, the 
first two categories were correlated to diseases, including 
the KEGG pathways “Melanoma” (4.6 times more genes 
than expected, p  =  3.1  ×  10−6) and “Bladder cancer” 
(5.4 times more genes than expected, p  =  1.4  ×  10−5). 
The third most significant category was the KEGG path-
way “Cell Cycle” (3.6 times more genes than expected, 
p = 1.8 × 10−5). The previously described gene VEGFA 
a
b
Fig. 4 Box plots of two selected examples in the eight tested groups. a The first miR-650 is only expressed in blood of strength athletes. b The 
second miR-140-5p is up-regulated in blood and plasma of strength as well as endurance athletes
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was not only contained in disease pathways but also in 
the Gene Ontology category “cell maturation” and the 
KEGG pathway “PI3 K-Akt signaling pathway”.
Specific correlation of miRNAs to diseases
To find correlations of miRNAs to diseases we queried 
the Human miRNA and disease database (HMDD) as 
described in the “Methods” section. Importantly, we 
only used unique combinations of miRNAs to diseases in 
the “circulation” data set from the HMDD, that includes 
512 associations for 240 miRNAs. Altogether, we found 
74 matches, i.e. 74 of the 512 entries in the HMDD con-
tained one of the 63 dys-regulated miRNAs. Almost 
50 % of the 63 miRNAs in turn were associated with at 
least one disease. The largest number of associations was 
found for hsa-mir-17, being correlated with 18 cancerous 
disorders. The associations between miRNAs and dis-
eases are summarized in Additional file 2: Table S2. The 
results indicate that the training mode potentially influ-
ence disease diagnosis by circulating miRNAs.
Specific miRNAs as indicators for fatigue
Although the 6-day training period itself seems to have 
only a limited influence on the miRNA profiles in total, 
specific miRNAs can potentially be altered in their abun-
dance by the fatigue. To quantify the effect of training 
we separately compared blood and plasma samples for 
endurance and strength athletes such that a total of four 
paired comparisons has been carried out: (1) plasma of 
strength athletes pre/post training (2) blood of strength 
athletes pre/post training (3) plasma of endurance athletes 
pre/post training and (4) blood of endurance athletes pre/
post training. To compare the results better to each other, 
raw p values have been taken into consideration. Of 388 
miRNAs, 24 were significant in comparison 1 (6.2 %), 56 
in comparison 2 (14.4 %), 21 in comparison 3 (5.4 %) and 
57 in comparison 4 (14.7). While the results for plasma 
miRNAs are close to the expected value of 5  % for the 
alpha level of 0.05, we observed an increased fraction of 
significant miRNAs for the comparison in blood of endur-
ance as well as strength athletes. The effects in blood were 
such substantial that despite the small cohort and the 
large number of features miR-17-5p remained significant 
even after correction for multiple testing in endurance 
athletes. Remarkably, this miRNA was also among the 
most dys-regulated between strength and endurance ath-
letes and its precursor was associated to 18 diseases in the 
HMDD. The expression of miR-17-5p is presented as box 
whisker plot in Fig.  7. Likewise, this figure presents the 
expression of miR-3200-3p, which is most significantly 
down-regulated following the training period in strength 
and endurance athletes. The ten most significant miRNAs 
(minimum p value in any of the four comparisons) are 
summarized in Table 2. As presented in Table 1, all signifi-
cantly changed miRNAs in blood following training are 
lower abundant as compared to the baseline value.
Fig. 5 Running sum that highlights “acute myocardial infarction” miRNAs to be significantly changed in strength versus power athletes
Page 9 of 13Hecksteden et al. J Transl Med  (2016) 14:219 
Correlation of miRNAs to other laboratory parameters
The athletes participating in this study were character-
ized for other common blood parameters as detailed in 
the “Methods” section. We correlated all miRNAs to all 
clinical parameters in a pair wise manner using Spearman 
correlation. To correct for multiple testing we applied the 
Bonferroni correction to minimize the number of false 
positive hits. Following this adjustment, 14 correlations 
of miRNAs with blood parameters remained significant. 
We found three correlations of the creatine kinase (CK) 
at day 5 with miR-18-3p, miR-33b-3p or miR-650. Both 
miR-1305 and miR-3198 correlated with IGF-BP3 after 
training and miR-128-3p correlated with the free testos-
terone. MiR-140-5p in plasma was negative correlated to 
hemoglobin while plasma miR-188-5p was positive cor-
related to hemoglobin.
Discussion
Levels of circulating miRNAs are not only altered in 
pathological processes but are also affected by training 
condition. In this study we examined the distribution 
of miRNAs in blood and plasma of strength and endur-
ance athletes before and after training. The influence of 
physiological processes, such as physical exercises, on 
the profiles of circulating miRNA may confound disease 
diagnosis by miRNAs potentially limiting the translation 
of miRNA profiles to clinics [18].
First, we provide evidence that miRNAs in blood and 
plasma are different between strength and endurance 
athletes and are also indicative for the overall fatigue 
status of competitive athletes. The effect sizes of differ-
ences in blood outreach the differences in plasma clearly. 
Fatigue induced changes were only detectable when using 
Fig. 6 Network analysis of target genes. For miRNAs dys-regulated between strength and endurance athletes we mapped target genes by 
functional experimental analysis. The most central gene was VEGFA, which is regulated by five miRNAs. As the table below the figure highlights, all 
miRNAs targeting VEGFA are up-regulated in endurance athletes
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a repeated measures approach, pointing to the need for 
an individualized interpretation of measured values. 
Moreover, we provide evidence that longitudinal meas-
urement of blood miRNAs may add to individualized and 
personalized training.
Different miRNAs have been described as markers for 
fatigue status or altered between strength and power ath-
letes (see “Background” section and [3, 9]). The respective 
miRNAs were also observed in our study. However usu-
ally other markers exceeded the effect sizes of the known 
markers substantially. This may be due to different fac-
tors. First, our study profiles over 12,000 miRNAs that 
are annotated in the version 16 of the miRBase (http://
www.mirbase.org). Second, we carried out a paired study 
set-up and no unpaired case–control study. Third we 
measured more individuals as most other studies. Alto-
gether, for 29 athletes four different full miRNomes were 
profiled, resulting in 116 profiles.
By investigating signaling cascades we discovered a high 
regulatory influence of miRNAs that are dys-regulated in 
strength and endurance athletes on several genes. Most 
significant was the regulatory influence of miRNAs on 
a vascular endothelia growth factor (VEGF), namely 
VEGFA. Increased capillary density in skeletal muscle is 
a well-known effect of exercise training which promotes 
oxygen supply during exercise by increasing diffusion 
area and reducing diffusion distance. Angiogenesis has 
been observed with various exercise modes including 
Fig. 7 Effect of training. The provided examples indicate that also short-time influences of miRNAs to training are observed
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endurance [19] and strength training [20]. However an 
increase in capillary density is generally observed with 
endurance training only, reflecting the requirements of 
aerobic energy production [21]. VEGF is a key pro-angio-
genic regulator of capillary growth in response to physical 
exercise [22]. Therefore, at first sight, the higher expres-
sion of miRNAs which (down-) regulate VEGF seems sur-
prising. However, capillary growth in response to exercise 
training is a highly regulated process involving a wealth 
of pro- as well as anti-angiogenic factors [21]. Two of 
the most important regulators promoting VEGF expres-
sion during exercise are AMP-activated protein kinase 
(AMPK) [23] and the transcriptional co-activator PGC-1α 
[24], which are also fundamental for the adaptation to 
endurance training [25]. Therefore, avoiding excessive 
angiogenesis caused by the targeted activation of these 
Table 1 KEGG and GO enrichment analysis
Significant categories containing at least three times more genes than expected by chance. Provided are the category name, the database where data have been 
extracted, the number of targets genes of the 63 miRNAs of this category, the expected number of genes given the 2098 background genes, the enrichment factor, 
and the p value following adjustment for multiple testing
Category Database Target genes  
on category
Expectation  
value
Enrichment p value
Melanoma KEGG 17 3.7 4.6 3.10E−06
Bladder cancer KEGG 13 2.4 5.4 1.36E−05
Cell cycle KEGG 19 5.3 3.6 1.83E−05
Glioma KEGG 15 3.4 4.4 1.83E−05
G1_phase(4) & mitotic_G1_phase(5) GO 11 1.3 8.3 2.34E−05
Viral carcinogenesis KEGG 20 6.0 3.3 2.59E−05
Pancreatic cancer KEGG 16 4.1 4.0 2.72E−05
Chronic myeloid leukemia KEGG 17 4.6 3.7 3.04E−05
Non-small cell lung cancer KEGG 12 3.1 3.9 5.86E−04
p53 signaling pathway KEGG 11 3.2 3.4 3.44E−03
Thyroid cancer KEGG 6 1.4 4.3 2.67E−02
Biological_phase(2) GO 15 4.9 3.1 4.68E−02
Cell_cycle_phase(3)&mitotic_cell_cycle_phase(4) GO 15 4.6 3.3 4.68E−02
Cell_maturation(5) GO 14 4.2 3.3 4.68E−02
Regulation_of_fibroblast_proliferation(5) GO 12 3.3 3.6 4.68E−02
Positive_regulation_of_fibroblast_proliferation(5) GO 10 2.3 4.3 4.68E−02
Interphase(4) GO 9 1.9 4.8 4.68E−02
Hair_follicle_morphogenesis(4) GO 7 1.2 6.0 4.68E−02
Table 2 Pair-wise comparisons of prior- and post training for endurance and strength athletes in blood and plasma
The significance values are shown along with the AUC values. Significant findings are highlighted in italics
miRNA Plasma 
strength p
Plasma  
strength AUC
Blood 
strength p
Blood strength 
AUC
Plasma endur-
ance p
Plasma endur-
ance AUC
Blood  
endurance p
Blood 
endurance 
AUC
hsa-miR-17-5p 0.1017 0.39 0.7784 0.53 0.8919 0.47 0.0001 0.26
hsa-miR-454-3p 0.4262 0.52 0.5771 0.55 0.9280 0.48 0.0003 0.33
hsa-miR-20a-5p 0.3969 0.43 0.7346 0.44 0.8167 0.56 0.0005 0.29
hsa-miR-590-5p 0.1679 0.39 0.0007 0.27 0.4055 0.58 0.2603 0.36
hsa-miR-
3200-3p
0.1099 0.67 0.0009 0.35 0.3392 0.59 0.0064 0.26
hsa-miR-29c-3p 0.0363 0.67 0.0010 0.34 0.6568 0.55 0.7085 0.50
hsa-miR-27b-3p 0.8400 0.52 0.3308 0.54 0.2059 0.57 0.0013 0.27
hsa-miR-
513a-5p
0.7051 0.54 0.3726 0.42 0.0014 0.25 0.1464 0.60
hsa-miR-26b-5p 0.3362 0.41 0.1040 0.65 0.4129 0.58 0.0014 0.31
hsa-miR-1246 0.0019 0.86 0.9294 0.60 0.2875 0.55 0.6481 0.59
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pathways with competitive endurance training seems to 
be a plausible explanation for this finding.
Besides, it is important to understand the variability of 
miRNAs dependent on the training (including long term 
effects but also short term effects) since miRNAs are 
important disease markers. This in turn means that inten-
sive, long-term training or even one single exhaustive event 
may confound disease diagnosis substantially. Similar 
effects are e.g. known for cardiac markers such as cardiac 
troponin and BNP [26, 27]. As shown in the “Results” sec-
tion, many miRNAs are associated with different diseases. 
Building on these results we investigated miRNA changes 
as result of the training condition. We carried out a com-
prehensive literature research for the most significantly 
changed markers in blood, serum and plasma, including 
46 markers that had adjusted p-values of below 10−10 in 
any of the two comparisons. The most significantly altered 
miR-650 was correlated to a range of different patholo-
gies, including heart failure [28], congenital heart disease 
[29], diabetic ischemic heart failure [30] and different can-
cer types (gastric cancer [31], melanoma [32], leukemia 
[33], hepatocellular carcinoma [34], glioma [35], colorec-
tal cancer [36] and lung cancer [37]). Other key miRNAs 
included miR-221-3p as marker for Non-ST-Segment and 
ST-Segment-Elevation Myocardial Infarction [38] and 
stroke [39]. In the latter publication another miRNA sig-
nificantly affected in our study was described: miR-140-5p. 
The same holds for miR-221-3p and miR-98-5p in preec-
lamptic patients [40]. Another study highlighted two miR-
NAs (again miR-140-5p as well as miR-532-5p) linked to 
type 2 diabetes that change with insulin sensitization [41]. 
The same two miRNAs have been found as markers for 
obesity [42]. Beyond these examples we extracted 231 hits 
for the 47 miRNAs (for 31 miRNAs at least a single hit was 
found) from PubMed (http://www.ncbi.nlm.nih.gov/pub-
med) in 211 different publications.
The overall high correlation of miRNAs affected by 
training to diseases provide evidence that the train-
ing condition is an important confounding vari-
able for miRNA biomarker studies that has to be taken 
into account in developing diagnostic and prognostic 
signatures.
Conclusion
This study represents the most comprehensive miRNA 
atlas of athletes to date. Our study set-up that includes 
four measurements per individual athlete allowed for 
quantifying differences in strength and endurance ath-
letes, in serum and plasma and before and after a 6 days 
training camp.
Overall, we report a limited immediate influence of 
the 6  days training on the miRNA profiles overall but 
describe substantial differences between profiles of 
strength and endurance athletes. miRNAs especially 
expressed in endurance athletes but less expressed in 
strength athletes significantly targeted VEGFA. These 
differences in blood by far exceeded the differences in 
plasma, which have already been described. Additionally, 
we provide evidence that miRNA profiles prior to exer-
cise correlate very well with measurements of creatine 
kinase carried out following 5 days of physical training.
Finally, we describe that the miRNAs that are affected 
by exercising according to our results are important dis-
ease markers. For a diagnosis or prognosis of human 
pathologies the amount and kind of physical training 
conducted prior to blood sampling is in consequence a 
very important confounding variable.
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